Shop
eStoreRx™
Online Supplement Dispensary
Easy direct-to-patient ordering & fulfilment for Lifelong Wellness, eStoreRx™ is offered as part of the WholePractice membership or as a stand-alone program.
For over 40 years, Biotics Research Corporation has revolutionized the nutritional supplement industry by utilizing “The Best of Science and Nature”. Combining nature’s principles with scientific ingenuity, our products magnify the nutritional
This inclusive membership contains all of the the tools you need to grow your business, including WholeLifeRx™, Nimativ®, WholeLifeQ™, eStoreRx™ and Practice Success Programs.
Easy direct-to-patient ordering & fulfilment for Lifelong Wellness, eStoreRx™ is offered as part of the WholePractice membership or as a stand-alone program.
August 30 2024
The Journal of Obesity & Metabolic Syndrome recently published the results of a randomized, double-blind, and placebo-controlled clinical trial ev...
JAMA Network Open recently published results of a randomized, open-label, active parallel-controlled clinical trial comparing an intermittent fasting program to both metformin and empagliflozin in Chinese adults with early type 2 diabetes. Known as the EARLY (Exploration of Treatment of Newly Diagnosed Overweight/Obese Type 2 Diabetes Mellitus) study, 405 participants were randomized in a 1:1:1 ratio to either metformin, empagliflozin, or the 5:2 MR, the latter consisting of 2 non-consecutive fasting days and 5 days of usual intake per week and meal replacement (MR) diet. Participants following the 5:2 MR had, within 1 week, 5 days of consuming their usual breakfast and lunch but a meal replacement for dinner, and on the 2 non-consecutive days, only consumed 1 meal replacement for a daily energy intake of 500 kcal for women and 600 kcal for men (on those 2 days). The 2 meal replacement formulations provided 17-20g of protein per serving, with ingredients including medium chain triglycerides, DHA, extra-virgin olive oil, etc.
The study was 16 weeks long with 8 weeks of additional follow-up; hemoglobin A1c (HbA1c) was the primary endpoint. The 5:2 MR approach was found to be superior to either drug in terms of glycemic control and weight loss. The HbA1c was reduced by 1.9% in this group, a significantly greater increase than either medication (e.g. metformin -1.6% and empagliflozin -1.5%). The 5:2 MR program also resulted in more significant and sustained reductions in weight loss and waist circumference; a weight loss of −9.7 kg with 5:2 MR versus −5.5 kg and -5.8 kg in the medication groups. There were similar improvements in fasting glucose and insulin, C-peptide levels, and HOMA-IR between groups, but more favorable changes in blood pressure, triglycerides, and HDL-C in the 5:2 MR group.
Submit this form and you'll receive our latest news and updates.
*These statements have not been evaluated by the Food and Drug Administration. This product has not intended to diagnose, treat, cure, or prevent any disease.
© 2023 Biotics Research Corporation - All Rights Reserved
Submit your comment